fulvestrant has been researched along with 3,3'-diindolylmethane in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bjeldanes, LF; Firestone, GL; Leong, H; Riby, JE | 1 |
| Geliebter, J; George, AL; Kamat, A; Rajoria, S; Schantz, SP; Suriano, R; Tiwari, RK | 1 |
2 other study(ies) available for fulvestrant and 3,3'-diindolylmethane
| Article | Year |
|---|---|
Potent ligand-independent estrogen receptor activation by 3,3'-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Cycloheximide; Endometrial Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Flavonoids; Fulvestrant; Humans; Indoles; Isoquinolines; Ligands; MAP Kinase Signaling System; Phosphoprotein Phosphatases; Phosphorylation; Point Mutation; Sulfonamides; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2004 |
Molecular target based combinational therapeutic approaches in thyroid cancer.
Topics: Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Culture Media, Conditioned; Down-Regulation; Estradiol; Estrogens; Female; Fulvestrant; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2012 |